Gilead expands its royalty-free lenacapavir voluntary licences to cover once-yearly PrEP, including Eva Pharma’s licence

An expansion of an existing voluntary licence held by an Egyptian manufacturer, covering 120 high-incidence countries most of which are in Africa.


Coverage: The Meridian legal market record (editorial).

An expansion of an existing voluntary licence held by an Egyptian manufacturer, covering 120 high-incidence countries most of which are in Africa.

Record ID TX-AFR-2026-0070
Record type Commercial IP transaction
Transaction type Licence extension, Non-exclusive licence
IP rights patent, regulatory data, know-how
Status Amended
Qualifying date 2026-09-16
Sector Life sciences · HIV prevention (antiretrovirals)
African markets Egypt, South Africa
Licensed territory 120 high-incidence, resource-limited countries (primarily low- and lower-middle-income).
Disclosed value Not disclosed in the sources reviewed.
Evidence Primary source, independently corroborated · 2 source(s)
Last verified 2026-10-25

Parties

  • Gilead Sciences, Inc. (United States): licensor
  • Eva Pharma for Pharmaceutical Industries S.A.E. (Egypt): licensee, manufacturer
  • Dr. Reddy's Laboratories Limited (India): licensee
  • Hetero (India): licensee

Key terms

  • Interest: non-exclusive royalty-free voluntary licence (scope expanded); Exclusivity: non-exclusive; Territorial scope: 120 high-incidence countries; Term: Royalty-free; term not stated
  • Financial terms as reported: “six royalty-free voluntary licensing agreements”

Sources

  1. Gilead accelerates global access planning for investigational once-yearly lenacapavir for HIV prevention, Gilead Sciences, 2026-09-16
  2. Gilead extends lenacapavir licensing deals to cover investigational once yearly HIV prevention shot, Biopharma Asia, 2026-10-20

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.